By Foo Yun Chee
BRUSSELS (Reuters) -U.S. genetic testing company Illumina was hit with a record 432-million-euro ($476 million) EU antitrust fine on Wednesday for closing its takeover of Grail before securing EU antitrust approval.
Illumina has been fighting the EU competition watchdog on several fronts since it was forced to seek its approval in 2021 despite the deal falling short of the EU turnover threshold for scrutiny.
The European Commission said the size of the fine, amounting to 10% of Illumina’s global revenue and the maximum allowed under EU merger rules for such infringements, underscored the seriousness of the offence and aimed to deter such conduct.
By closing the deal prematurely, Illumina was able to exercise a decisive influence over GRAIL, which it did, the EU enforcer said, calling the gun-jumping an unprecedented and very serious infringement.
“If companies merge before our clearance, they breach our rules. Illumina and GRAIL knowingly and deliberately did so by implementing their tie-up as we were still investigating,” EU antitrust chief Margrethe Vestager said in a statement.
Grail was given a symbolic 1,000 euro fine for its active role in the infringement, the first time a target company has been sanctioned.
Illumina criticised the fine as ‘unlawful, inappropriate, and disproportionate’ and said it would appeal the penalty. It has set aside $458 million, representing 10% of its consolidated annual revenue for fiscal year 2022, for the fine.
“We closed the transaction in 2021 because there was no impediment to closing in the US and the deal timeframe would have expired before the EC could reach a decision on the merits,” the company said in a statement.
“The deal timeframe relied on the EC’s public statements that it would not assert jurisdiction over mergers of this type until new guidelines were issued, yet the EC nonetheless asserted jurisdiction over the merger before issuing the promised guidelines.”
($1 = 0.9072 euros)
(Reporting by Foo Yun Chee;Editing by Elaine Hardcastle)
